Back to blog

Are you investing in the farm business? You should know that covid is not pulling anymore, obesity is in

The last three years have shown how quickly the situation can change, not only in the stock market as a whole, but also within a single sector. While as recently as the turn of 2020 and 2021, investments in shares of pharmaceutical companies focused on the development and delivery of an effective and safe vaccine against the SARS-CoV-2 coronavirus seemed promising, today completely different companies are leading the way within the pharmaceutical sector.

Are you investing in the farm business? You should know that covid is not pulling anymore, obesity is in

Moderna, Pfizer, BioNTech, but also AstraZeneca and Novavax. These are the pharmaceutical companies that, after the outbreak of the coronavirus pandemic, literally rushed to develop a vaccine against the virus that has claimed several million lives worldwide. And many of these companies have celebrated success, which has duly reflected in the rise of their market value.

But as the pandemic faded, the world began to return to normal, and with it, the interest in the shares of companies that had worked on the coronavirus and everything around it gradually declined. Perhaps this development is most evident in the biotechnology company Moderna. Its shares could be bought for around $20 at the beginning of 2020. But in just 20 months, their value has risen to $450, a 22.5-fold increase. *

Today, a Moderna share can be bought for $70.* In addition, Moderna is experiencing a big drop in sales and is operating in the red. The main reason for this is that Moderna has not yet been able to capitalize on the knowledge gained during the cover-up elsewhere and seems to be missing the train.

Snímek obrazovky 2023-11-20 v 10.34.36

Moderna Inc's share price performance over the last 5 years (source: www.investing.com)*

But that doesn't mean that investors should disregard the pharmaceutical sector as a whole. In fact, the Covid pandemic has only temporarily drowned out another pandemic that, while not infectious, is spreading as quickly as respiratory viruses. The world (especially the developed world) has been facing an obesity pandemic for many years. Hand in hand with obesity is the spread of diabetes.

It is on a cure for diabetes that the Danish pharmaceutical company Novo Nordisk is betting. It is one of the most successful pharmaceutical companies in the world and one of the most valuable European companies ever. Its success is likely to be compounded, as Novo Nordisk has recently come up with products that can significantly reduce body weight. These are the prescription drugs Wegova and Ozempic.

Similar products are or will be marketed by the US pharmaceutical group Eli Lilly. Although its drug Mounjaro is intended for the treatment of diabetes, it can also reduce weight. In addition, a few days ago, the US Food and Drug Administration (FDA) approved Eli Lilly's weight-loss drug, which will be available on the market under the name Zepbond.

The shares of both companies are thus flying upwards. Eli Lilly is up nearly 64 percent since the beginning of this year, and Novo Nordisk shares have added nearly 47 percent.* Eli Lilly's market capitalization currently stands at more than $567 billion, making the company more than $200 billion more valuable than the world's largest and most valuable pharmaceutical group, Johnson & Johnson, until recently. Novo Nordisk is already closing in on Johnson & Johnson.

Snímek obrazovky 2023-11-20 v 10.35.31

Eli Lilly and Company's share price performance over the last 5 years (source: www.investing.com)*

Snímek obrazovky 2023-11-20 v 10.36.21

Novo Nordisk A/S share price development over the last 5 years (source: www.investing.com)*

It might seem like a bad time to invest in shares of either Eli Lilly or Novo Nordisk. The fact is, of course, that those who invested at least at the beginning of this year have undoubted reason to rejoice. But that does not mean that such an investment would not be worth considering now. The market for obesity drugs is at the very beginning of its growth. According to the US investment bank Goldman Sachs, this market will be worth around six billion dollars this year. But it is set to grow to at least $100 billion by the end of this decade.[1] It is therefore very likely that Novo Nordisk and Eli Lilly will both have a significant share of the market. Even with this, the obesitology segment will be attractive for other players to enter. However, Novo Nordisk and Eli Lilly have a big head start so far.

---

* Past performance is no guarantee of future results.

[1] Forward-looking statements are based on assumptions and current expectations, which may be inaccurate, or on the current economic environment, which may change. Such statements are not guarantees of future performance. They involve risks and other uncertainties that are difficult to predict. Results may differ materially from those expressed or implied by any forward-looking statements.

Read more

SK Hynix Hits New High as It Builds South Korea’s Largest Data Center

SK Hynix Hits New High as It Builds South Korea’s Largest Data Center

For SK Hynix, a manufacturer of state-of-the-art semiconductors from Korea, 2025 has so far been as successful as the previous one. This proves that last year's 30% rise in share price was not accidental and the company is doing everything it can to maintain the momentum.* The latest is the plan to build the largest data center in cooperation with Amazon, which has the potential to strengthen the 50% increase in the value of shares since April, even further.

Apple and the Foldable iPhone: Could It Set New Sales Records?

Apple and the Foldable iPhone: Could It Set New Sales Records?

The first news about the possibility of starting production of a foldable iPhone bypassed technology enthusiasts at the end of last year, but unfortunately at that time it was only preliminary information, without a broader basis. We are currently in the middle of 2025 and analyst Ming-Chi Kuo of TF International Securities, a renowned expert on the Asian supply chain, commented on the situation. According to him, production of the foldable iPhone is likely to begin as early as 2026. Investors should not miss it, as this novelty would potentially have a chance to push stagnant sales.

Meta and Scale AI: What Will Zuckerberg Gain From the $14 Billion Bet?

Meta and Scale AI: What Will Zuckerberg Gain From the $14 Billion Bet?

At the beginning of last week, the first speculations appeared on the market about one of Meta's largest investments, namely the acquisition of a minority stake in the startup Scale AI founded by Alexander Wang. Preliminary information was subsequently confirmed on Friday, which also led investors to think about the possible impacts. Will Meta be able to reach the very top of AI innovation thanks to the new collaboration, or are the expectations too high? Will we see a new absolute high for Meta's share price soon?

Looking to Diversify Beyond U.S. Equities? M2C Is Going Public!

Looking to Diversify Beyond U.S. Equities? M2C Is Going Public!

When in 1992 a group of students decided to establish a company with the aim of providing services, probably none of them knew that three decades later, the company would stand on the threshold of the Prague Stock Exchange and head to America. Mark2 Corporation, M2C, has moved from a simple Facility Management (FM) to a high-tech ecosystem of services, which today operates in 13 countries in Europe, is expanding to the Middle East and the United States, and is preparing for an initial public offering (IPO) that you will soon be able to use.